Diagnostic evaluation of patients suspected to have collagen lysyl hydroxylase deficiency (Ehlers-Danlos Syndrome type VIA). May be useful when evaluating bone resorption (eg, osteoporosis). Preferred test for monitoring bone resorption and response to antiresorptive therapy is C-Telopeptide, Beta-Cross-Linked, Serum (0070416).
High Performance Liquid Chromatography (HPLC)
First morning void.
Transfer 8 mL urine to ARUP Standard Transport Tubes. (Min: 4 mL)
Ambient: Unacceptable; Refrigerated: 1 week; Frozen: 6 months
|0-11 months||353-560 µmol/mol crt||46-113 µmol/mol crt||0.13-0.20|
|1-3 years||108-400 µmol/mol crt||19-94 µmol/mol crt||0.18-0.24|
|4-9 years||117-325 µmol/mol crt||20-75 µmol/mol crt||0.19-0.25|
|10-14 years||81-267 µmol/mol crt||13-61 µmol/mol crt||0.17-0.27|
|15-19 years||38-80 µmol/mol crt||10-18 µmol/mol crt||0.20-0.26|
|20 years and older||20-40 µmol/mol crt||5-11 µmol/mol crt||0.23-0.29|
Pyridinoline and Deoxypyridinoline excretion follows a circadian rhythm. Reference intervals have been established on first morning void urine samples.
Compliance Statement B: For laboratory developed tests not using a RUO kit, and for FDA approved, cleared or 510(k) exempt assays with alterations. This test was developed and its performance characteristics determined by ARUP Laboratories. The U. S. Food and Drug Administration has not approved or cleared this test; however, FDA clearance or approval is not currently required for clinical use. The results are not intended to be used as the sole means for clinical diagnosis or patient management decisions.
|Component Test Code*||Component Chart Name||LOINC|
|0080347||PYD and DPD Interpretation|
- Deoxypyridinoline and Pyridinoline, HPLC